Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

Effectiveness of Post Muscle Inhibition Specific Joint Mobilization on Range of Motion and Pain in Patients With Mechanical Neck Pain

INTERVENTIONALInicio: 30 de ago de 2021ID: NCT05447338

ReclutandoClinicalTrials.gov

NEVA ONE One-Pass Reperfusion With the NeVa Stent-Retriever EMEA Registry

INTERVENTIONALInicio: 1 de jul de 2020ID: NCT04562194

ReclutandoFase 2ClinicalTrials.gov

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase

INTERVENTIONALInicio: 9 de ago de 2018ID: NCT02991469

ReclutandoFase 3ClinicalTrials.gov

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis

INTERVENTIONALInicio: 22 de sept de 2025ID: NCT07116967

ReclutandoClinicalTrials.gov

Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)

OBSERVATIONALInicio: 2 de sept de 2025ID: NCT07136467

ReclutandoClinicalTrials.gov

A Single-Center, Investigator-Blinded, Randomized, 4-Week, Parallel-Group, Superiority Study Comparing Contextual Factors-Enriched Standard Care Versus Standard Care Only for Patients with Mechanical Neck Pain (ContextualizAR Trial)

INTERVENTIONALInicio: 2 de may de 2024ID: NCT06361472

ReclutandoFase 3ClinicalTrials.gov

A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)

INTERVENTIONALInicio: 2 de dic de 2024ID: NCT06694805

ReclutandoFase 2ClinicalTrials.gov

A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis

INTERVENTIONALInicio: 11 de nov de 2024ID: NCT06655155

ReclutandoClinicalTrials.gov

Real World Evidence of First Line Treatment With Arsenic Trioxide Plus All Trans Retinoic Acid in Adult Patients With Acute Promyelocytic Leukemia

OBSERVATIONALInicio: 1 de mar de 2021ID: NCT04897490

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

INTERVENTIONALInicio: 10 de sept de 2025ID: NCT06919965

ReclutandoFase 3ClinicalTrials.gov

A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)

INTERVENTIONALInicio: 24 de ago de 2023ID: NCT06023589

ReclutandoFase 2ClinicalTrials.gov

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

INTERVENTIONALInicio: 20 de jun de 2023ID: NCT05789082

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

INTERVENTIONALInicio: 16 de jul de 2025ID: NCT06997497

ReclutandoFase 2ClinicalTrials.gov

A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT

INTERVENTIONALInicio: 25 de sept de 2024ID: NCT06462235

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)

INTERVENTIONALInicio: 11 de sept de 2024ID: NCT06572384

ReclutandoFase 2ClinicalTrials.gov

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

INTERVENTIONALInicio: 5 de abr de 2021ID: NCT04728893

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

INTERVENTIONALInicio: 24 de may de 2024ID: NCT06419374

ReclutandoFase 2ClinicalTrials.gov

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis

INTERVENTIONALInicio: 10 de oct de 2024ID: NCT06598943

ReclutandoFase 2ClinicalTrials.gov

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

INTERVENTIONALInicio: 27 de jun de 2025ID: NCT07082738

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

INTERVENTIONALInicio: 16 de feb de 2024ID: NCT06120140